Crown Bioscience Named Fierce CRO Award Winner for Excellence in Global Operations
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announces it has been named the Fierce CRO Award winner in the Excellence in Global Operations category by Fierce Biotech.
The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations, recognizing CROs demonstrating outstanding performance, innovation, and leadership in delivering high-quality research and development services. The awards emphasize the critical role CROs play in advancing life sciences research and improving patient outcomes.
John Gu, Chief Executive Officer of Crown Bioscience, stated, "Winning this award for Excellence in Global Operations is a proud moment for Crown Bioscience and a meaningful recognition of the outstanding work delivered by our global operations team. Alongside our 2024 Excellence in Client Services and Partnership Award, these accolades highlight our unwavering commitment to serving clients with excellence and our contribution to discovering innovative new medicines."
Fierce CRO Award finalists and winners are evaluated based on Innovation and Impact, Measurable Outcomes, Sustainability and Scalability, and Ethical and Regulatory Adherence. Winners are featured in the Fierce CRO Report. Click here to read the report: https://www.fiercebiotech.com/cro/excellence-global-operations
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit www.crownbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618264941/en/
Contacts
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taylor Wessing Diversifies Its International Strategy17.12.2025 15:05:00 CET | Press Release
International law firm Taylor Wessing is set to diversify its strategy within its international alliance, in order to push international growth and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217415857/en/ Dr. Oliver Bertram, Global Co-Chair at Taylor Wessing The English part of the partnership is seeking a merger with US law firm Winston & Strawn and would – depending on a corresponding partner decision, which is still pending – leave the Taylor Wessing alliance at the end of April 2026. Both parties wish to continue their successful joint international client work unchanged. Therefore, collaboration between Taylor Wessing and future Anglo-American firm Winston Taylor will continue seamlessly based on a cooperation agreement, ensuring that clients will not experience any change in their collaboration with Taylor Wessing. With the firm’s new open strategy, Taylor Wessing equally meets the strategic requirem
ISACA to Lead Global Credentialing for CMMC Cybersecurity Framework as International Cyber Readiness Standards Rise17.12.2025 15:00:00 CET | Press Release
As cyber threats escalate and governments raise expectations around operational resilience, ISACA has been appointed to lead the global credentialing programme for the U.S. DoW’s Cybersecurity Maturity Model Certification (CMMC) program. The appointment positions ISACA – the international association for cybersecurity, audit and digital trust – as the exclusive CMMC Assessor and Instructor Certification Organization (CAICO), responsible for training, examining and certifying professionals, assessors, and instructors across the CMMC ecosystem. Originally developed by the U.S. DoW to protect sensitive unclassified information within its global supply chain, CMMC is increasingly relevant to European defence, aerospace, engineering and high-technology companies participating in transatlantic programmes. As the framework is phased into U.S. procurement from 2025 to 2028, many European organisations that handle Controlled Unclassified Information (CUI) or Federal Contract Information (FCI),
ASN Bank Signs a Contract With HCLTech to Accelerate Digital Transformation and Enhance Customer Experience17.12.2025 14:43:00 CET | Press Release
HCLTech, a leading global technology company, today announced that it has been selected as a strategic partner by ASN Bank (formerly de Volksbank), the fourth-largest retail bank in the Netherlands. As part of its new strategy ‘Simplify and Grow’, ASN Bank aims to modernise and standardise its IT architecture, which will involve consolidating IT services, simplifying the vendor landscape and building a future-ready organisation. Under the multi-year agreement, HCLTech will support ASN Bank’s enterprise applications, and streamline services through a distributed delivery model to enhance efficiency and customer experience. Michel Ruijterman, Chief Information Officer, ASN Bank: “By signing this agreement , HCLTech’s proven track record in delivering scalable, innovative solutions tailored to the financial services sector means we can now confidently press on with streamlining our business by reducing the number of existing products and aligning the underlying processes and systems under
Riskified Announces Ascend 2026: “Intelligence in Motion” for the Next Era of Ecommerce17.12.2025 14:30:00 CET | Press Release
Riskified (NYSE:RSKD), the leader in AI fraud and risk management for ecommerce, has announced that its premier global summit Ascend will once again be held as a global event series in 2026. Kicking off with North America (May) and continuing to Europe (June), Australia (August), China (September), and Japan (October), Ascend will convene each region’s largest merchants, industry experts, and technology leaders to discover the latest AI advancements and innovative strategies to propel ecommerce success. “Having pioneered using AI to fight ecommerce fraud and policy abuse over the past 10+ years, it’s equally exhilarating as it is concerning to witness the dramatic impact AI and agentic commerce are making on our industry. As risk grows more complex and shopper expectations rise, fraud teams and customer experience leaders can’t afford to sit back: they have to rise up and design the future themselves,” said Jeff Otto, Chief Marketing Officer of Riskified. “Ascend 2026 will explore how
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting17.12.2025 13:00:00 CET | Press Release
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Board), will comprise the Board of the Company until the trial listed in late April/early May 2026. The Antigua High Court decision arises from a hearing that took place on 27 October 2025, at which applicants SAIF Partners IV L.P., OrbiMed Partners Master Fund Limited and 1Globe Capital LLC each sought injunctions to confirm the composition of their respective favoured Boards, pending determination of a dispute over the outcome of the Company’s Special Shareholders Meeting on 8 July 2025 (the SSM Dispute). The hearing of the SSM Dispute has been scheduled to take place in the Antigua High Court in late April/early May 2026, with judgment to be de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom